Success Metrics

Completion Rate
0%(0/1)
Active Trials
4(57%)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_2
6
86%

Phase Distribution

0

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
6(85.7%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Terminated(1)
Other(2)

Detailed Status

Recruiting3
unknown2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (85.7%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting114%
unknown229%
terminated114%
recruiting343%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
recruitingphase_2

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471
recruitingphase_3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347
active_not_recruitingphase_2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401
unknownphase_2

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

NCT04585152
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT07634471Phase 2

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT05406401Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active Not Recruiting
NCT04585152Phase 2

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

Unknown
NCT04246359Phase 2

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Unknown
NCT04402580Phase 2

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Terminated

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7